• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Eric T. Wong, MD


  • Wong ET, Lok E, Swanson KD.
    Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
    Cancer Med. 2015 Mar;4(3):383-91.
  • Wang F, Remke M, Bhat K, Wong ET, Zhou S, Ramaswamy V, Dubuc A, Fonkem E, Salem S, Zhang H, Hsieh TC, O'Rourke ST, Wu L, Li DW, Hawkins C, Kohane IS, Wu JM, Wu M, Taylor MD, Wu E.
    A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma.
    Oncotarget. 2015 Feb 20;6(5):2709-24.
  • Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, Dahlberg SE, Huberman MS, Costa DB.
    Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.
    Lung Cancer. 2015 Feb 4.
  • Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ, Doherty L, Lafrankie D, Gaffey SC, Gerard M, Smith KH, McCluskey C, Phuphanich S, Wen PY.
    Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
    Neurology. 2015 Jan 20;84(3):280-6.
  • Fonkem E, Lok E, Robison D, Gautam S, Wong ET.
    The natural history of intravascular lymphomatosis.
    Cancer Med. 2014 Jun 14.
  • Scheidegger R, Wong ET, Alsop DC.
    Contributors to contrast between glioma and brain tissue in chemical exchange saturation transfer sensitive imaging at 3Tesla.
    Neuroimage. 2014 May 20.
  • Elzinga G, Wong ET.
    Resolution of cystic enhancement to add-on tumor treating electric fields for recurrent glioblastoma after incomplete response to bevacizumab.
    Case Rep Neurol. 2014 Jan;6(1):109-15.
  • Lacouture ME, Davis ME, Elzinga G, Butowski N, Tran D, Villano JL, DiMeglio L, Davies AM, Wong ET.
    Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma.
    Semin Oncol. 2014 Jun;41 Suppl 4:S1-14.
  • Lok E, Chung AS, Swanson KD, Wong ET.
    Melanoma brain metastasis globally reconfigures chemokine and cytokine profiles in patient cerebrospinal fluid.
    Melanoma Res. 2014 Apr;24(2):120-30.
  • Wong ET, Lok E, Swanson KD, Gautam S, Engelhard HH, Lieberman F, Taillibert S, Ram Z, Villano JL.
    Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma.
    Cancer Med. 2014 Feb 14.
  • Butowski N, Wong ET, Mehta MP, Wilson LK.
    A roundtable discussion on the clinical challenges and options for the treatment of glioblastoma: introducing a novel modality, TTFields.
    Semin Oncol. 2013 Dec;40(6):S2-4.
  • McDuff SG, Taich ZJ, Lawson JD, Sanghvi P, Wong ET, Barker FG, Hochberg FH, Loeffler JS, Warnke PC, Murphy KT, Mundt AJ, Carter BS, McDonald CR, Chen CC.
    Neurocognitive assessment following whole brain radiation therapy and radiosurgery for patients with cerebral metastases.
    J Neurol Neurosurg Psychiatry. 2013 Dec;84(12):1384-91.
  • Chen WW, Balaj L, Liau LM, Samuels ML, Kotsopoulos SK, Maguire CA, Loguidice L, Soto H, Garrett M, Zhu LD, Sivaraman S, Chen C, Wong ET, Carter BS, Hochberg FH, Breakefield XO, Skog J.
    BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles.
    Mol Ther Nucleic Acids. 2013;2:e109.
  • Recht L, Mechtler LL, Wong ET, O'Connor PC, Rodda BE.
    Steroid-sparing effect of corticorelin acetate in peritumoral cerebral edema is associated with improvement in steroid-induced myopathy.
    J Clin Oncol. 2013 Mar 20;31(9):1182-7.
  • Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD, Mikkelsen T, Rosenfeld S, Sarantopoulos J, Meyers CA, Fielding RM, Elian K, Wang X, Lawrence B, Shing M, Kelsey S, Castaigne JP, Wen PY.
    Phase I study of GRN1005 in recurrent malignant glioma.
    Clin Cancer Res. 2013 Mar 15;19(6):1567-76.
  • Lu R, Wu C, Guo L, Liu Y, Mo W, Wang H, Ding J, Wong ET, Yu M.
    The role of brevican in glioma: promoting tumor cell motility in vitro and in vivo.
    BMC Cancer. 2012;12:607.
  • Floyd SR, Kasper EM, Uhlmann EJ, Fonkem E, Wong ET, Mahadevan A.
    Hypofractionated Radiotherapy and Stereotactic Boost with Concurrent and Adjuvant Temozolamide for Glioblastoma in Good Performance Status Elderly Patients - Early Results of a Phase II Trial.
    Frontiers In Oncology. 2012;2:122.
  • Fonkem E, Uhlmann EJ, Floyd SR, Mahadevan A, Kasper E, Eton O, Wong ET.
    Melanoma brain metastasis: overview of current management and emerging targeted therapies.
    Expert Rev Neurother. 2012 Oct;12(10):1207-15.
  • Fonkem E, Wong ET.
    NovoTTF-100A: a new treatment modality for recurrent glioblastoma.
    Expert Rev Neurother. 2012 Aug;12(8):895-9.
  • Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, DbalĂ˝ V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH.
    NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.
    Eur J Cancer. 2012 Sep;48(14):2192-202.
  • Mahadevan A, Floyd S, Wong E, Chen C, Kasper E.
    Clinical outcome after Hypofractionated Stereotactic Radiotherapy (HSRT) for benign skull base tumors.
    Comput Aided Surg. 2011 Apr 6.
  • Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S.
    Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis.
    J Natl Compr Canc Netw. 2011 Apr;9(4):403-7.
  • Lehtinen MK, Zappaterra MW, Chen X, Yang YJ, Hill AD, Lun M, Maynard T, Gonzalez D, Kim S, Ye P, D'Ercole AJ, Wong ET, Lamantia AS, Walsh CA.
    The cerebrospinal fluid provides a proliferative niche for neural progenitor cells.
    Neuron. 2011 Mar 10;69(5):893-905.
  • Wong ET, Brem S.
    Taming glioblastoma by targeting angiogenesis: 3 years later.
    J Clin Oncol. 2011 Jan 10;29(2):124-6.
  • Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE, Wen PY.
    Phase I Study of Vandetanib with Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma.
    Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):85-90.
  • Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM.
    Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group.
    J Clin Oncol. 2010 Apr 10;28(11):1963-72.
  • Wong KK, Engelman JA, Cantley LC.
    Targeting the PI3K signaling pathway in cancer.
    Curr Opin Genet Dev. 2010 Feb;20(1):87-90. Review.
  • Park S,Zhao D,Hatanpaa KJ,Mickey BE,Saha D,Boothman DA,Story MD,Wong ET,Burma S,Georgescu MM,Rangnekar VM,Chauncey SS,Habib AA.
    RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN.
    Cancer Res. 2009 May 15;69(10):4107-11.
  • Wong ET,Huberman M,Lu XQ,Mahadevan A.
    Bevacizumab reverses cerebral radiation necrosis.
    J Clin Oncol. 2008 Dec 1;26(34):5649-50.
  • Drappatz J,Wong ET,Schiff D,Kesari S,Batchelor TT,Doherty L,Lafrankie DC,Ramakrishna N,Weiss S,Smith ST,Ciampa A,Zimmerman J,Ostrowsky L,David K,Norden A,Barron L,Sceppa C,Black PM,Wen PY.
    A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme.
    Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):222-7.
  • Lu XQ, Shanmugham LN, Mahadevan A, Nedea E, Stevenson MA, Kaplan I, Wong ET, La Rosa S, Wang F, Berman SM.
    Organ deformation and dose coverage in robotic respiratory-tracking radiotherapy.
    Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):281-9.
  • Chowdhary S, Wong ET.
    Bevacizumab combined with irinotecan for recurrent glioblastoma multiforme--improvement over available therapy?.
    Nat Clin Pract Neurol. 2008 May;4(5):242-3.
  • Wong ET, Alsop D, Lee D, Tam A, Barron L, Bloom J, Gautam S, Wu JK.
    Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas.
    Cerebrospinal Fluid Res. 2008;5:1.
  • Wu WC, Buxton RB, Wong EC.
    Vascular space occupancy weighted imaging with control of residual blood signal and higher contrast-to-noise ratio.
    IEEE Trans Med Imaging. 2007 Oct;26(10):1319-27.
  • Wong ET, Brem S.
    Taming glioblastoma: targeting angiogenesis.
    J Clin Oncol. 2007 Oct 20;25(30):4705-6.
  • Wong ET, Lee D, Tam A, Gautam S, Wu JK.
    Matrix metalloprotease-9 in cerebrospinal fluid correlates with disease activity in lymphomatous meningitis.
    Clin Lymphoma Myeloma. 2007 Jan;7(4):305-8.
  • Wong ET.
    Is protracted low-dose temozolomide feasible in glioma patients?.
    Neurology. 2006 Aug 8;67(3):543-4; author reply 543-4.
  • Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H, Libermann TA, Raisanen JM, Ashfaq R, Wong ET, Wu J, Elliott R, Habib AA.
    Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Cancer Res. 2006 Jan 15;66(2):867-74.
  • Wong ET.
    Tumor growth, invasion, and angiogenesis in malignant gliomas.
    J Neurooncol. 2006 May;77(3):295-6.
  • Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK.
    Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.
    J Clin Oncol. 1999 Aug;17(8):2572.